InsidersTradesSigma
Total declarations
Companies
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
6
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-28.2%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Meckler Jeffrey A, Chief Executive Officer. Officer active across 2 companies, notably Travere Therapeutics, Inc.. Cumulatively, 16 disclosures have been logged. Split: 6 buys · 0 sell. Total volume traded: €209k. History available since 14 May 2021. The latest transaction was disclosed on 22 December 2025 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Meckler Jeffrey A
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations16 total
216,617 shares@ US$2.0345.9% of flowCommon StockSEC:0001493152-25-029355:0
6,068 shares@ US$8.30249.7% of flowCommon StockSEC:0001641172-25-021376:0
6,500 shares0Common StockSEC:0001415889-25-013500:0
42,553 shares@ US$1.1759.0% of flowCommon stockSEC:0001493152-24-047808:0
40,000 shares@ US$10.48100.0% of flowCommon StockSEC:0001415889-24-024117:0
84,932 shares@ US$1.82526.9% of flowCommon stockSEC:0001493152-24-030839:0
6,500 shares0Common StockSEC:0001415889-24-012848:0
4,500 shares0Common StockSEC:0001209191-23-030961:0
400 shares@ US$1.76370.1% of flowCommon stockSEC:0001493152-22-033241:0
Canonical exit: 16 Feb 2023 (T+90)
10,308 shares@ US$2.805.5% of flowCommon stockSEC:0001493152-22-025578:0
Canonical exit: 7 Dec 2022 (T+90)
1,060 shares@ US$2.440.5% of flowCommon stockSEC:0001493152-22-025319:0
Canonical exit: 5 Dec 2022 (T+90)
19,727 shares@ US$2.630.95% mcap15.9% of flowCommon stockSEC:0001493152-22-016027:0
Canonical exit: 4 Sept 2022 (T+90)
3,000 shares0Common StockSEC:0001209191-22-028697:0
11,187 shares@ US$5.827.0% of flowCommon StockSEC:0001493152-21-029297:0
Canonical exit: 16 Feb 2022 (T+90)
12,000 shares@ US$7.008.7% of flowCommon StockSEC:0001493152-21-022936:0
Canonical exit: 13 Dec 2021 (T+90)
3,000 shares0Common StockSEC:0001209191-21-033849:0
16 of 16 declarations
About Meckler Jeffrey A
Meckler Jeffrey A is Président et Directeur Général. Across the 16 filings recorded, the most recent filings, from 2021-05-18 to 2025-12-29, show purchases of EUR 209315 and no sales, with the dominant transaction nature listed as Attribution. The main filings relate to Travere Therapeutics, Inc. and Indaptus Therapeutics, Inc.
